Swiss biotech firm Orbis Medicines develops AI-driven high-throughput drug discovery processes to design novel oral macrocyclic drugs | Top 100 Swiss Innovations
Image source: Orbis Medicines
Swiss biotech firm Orbis Medicines was founded in 2021, dedicated to developing an AI-driven high-throughput drug discovery process. This process integrates artificial intelligence, automated chemical synthesis and biological activity detection technologies, enabling rapid screening and optimization of macrocyclic drug molecules, and improving the oral bioavailability of candidate drugs.
Orbis Medicines is a spin-off company of École Polytechnique Fédérale de Lausanne (EPFL), co-founded by Christian Heinis, Sevan Habeshian and Morten Graugaard. Christian Heinis, Scientific Co-founder, has been teaching at EPFL since 2008, with long-term focus on cyclic peptide drug design and high-throughput screening technologies. Sevan Habeshian, Technical Co-founder, holds a PhD in Chemical Biology from EPFL, and has nearly 7 years of experience in DNA-encoded compound library design, chemical synthesis and drug screening at X-Chem. Morten Graugaard, Chief Business Officer of the company, holds a Master's degree in Human Biology from the University of Copenhagen, and previously served as Corporate Development Director at Lundbeck and Partner at Novo Holdings.
Image source: Endpoints News
At present, traditional small-molecule drugs can hardly act effectively on some complex disease targets. While biotherapeutic macromolecules such as antibodies, proteins and peptides can recognize and act on complex protein targets, they are vulnerable to degradation by gastric acid and digestive enzymes due to their large molecular weight, and meanwhile struggle to cross the intestinal epithelial barrier, resulting in low oral bioavailability, so they still need to be administered via subcutaneous injection or intravenous infusion. In addition, structural changes of biotherapeutic macromolecules have a great impact on drug activity and absorption performance. Traditional R&D requires repeated molecular design, chemical synthesis and experimental screening, which leads to long R&D cycles, high costs, and limited development efficiency of new oral macrocyclic drugs.
Image source: Orbis Medicines
Orbis Medicines has developed an AI-driven high-throughput drug discovery process that enables rapid screening and optimization of drug molecules, based on which it develops new synthetic macrocyclic compounds that can be administered orally.
Orbis Medicines' AI-driven high-throughput drug discovery process adopts the "Lab-in-the-Loop" R&D mode, with a complete "Design-Synthesize-Test-Analyze" cycle. First, Orbis screens initial active molecules that can bind to the target protein from its proprietary DNA-encoded library containing nearly 100 billion compounds. Then, combined with existing experimental data, it uses generative AI and machine learning models to design and optimize candidate drug molecules, and adopts automated high-throughput synthesis technology to synthesize and analyze up to about 100,000 cyclic macromolecular compounds within several weeks. Finally, it evaluates the target binding capacity, membrane permeability and stability of candidate molecules through biological activity detection, and feeds the actual detection results back to the AI model to improve the next round of molecular design and screening.
Compared with traditional macrocyclic compounds, the new synthetic macrocyclic compounds of Orbis Medicines can reduce the typical molecular weight to 500-1000 Daltons by adjusting the molecular skeleton, chemical composition and cyclic structure, lowering the difficulty for molecules to penetrate the intestinal epithelial barrier. At the same time, by introducing chemical building blocks such as unnatural amino acids, adjusting molecular side chains, amino acid arrangement order and cyclization connection modes, the structural diversity of the compounds is effectively expanded, making their potential chemical design space reach up to 10³⁰ structural combinations, which can optimize the binding capacity, membrane permeability and metabolic stability of molecules for different protein targets. In addition, this process adopts a fully chemical synthesis method for preparation, and does not need to rely on living cells to produce complete proteins or antibodies.
Orbis Medicines is currently focusing on the R&D of new oral macrocyclic drugs around immune and inflammatory diseases and cardiovascular metabolic diseases. Immune and inflammatory diseases are the company's independent R&D direction, with focus on developing oral candidate drugs targeting protein targets that have been verified by biologics. In terms of cardiovascular metabolic diseases, the company reached a multi-target drug discovery and licensing agreement with Novo Nordisk in September 2026. The two parties will use Orbis' AI-driven high-throughput drug discovery process to jointly develop new oral macrocyclic drugs for cardiovascular metabolic diseases, with the maximum potential value of the cooperation agreement reaching 1.4 billion US dollars.
In February 2024, the company completed a 26 million euro seed round of financing, co-led by Novo Holdings and Forbion. The funds are mainly used for the construction of the core drug R&D platform and the development of new oral macrocyclic drugs. In January 2025, the company completed another 90 million euro Series A financing, led by New Enterprise Associates, with follow-on investments from Lilly Ventures, Cormorant and the Danish Export and Investment Fund. The funds are mainly used to advance the R&D of new synthetic macrocyclic compound candidate drugs.
Orbis Medicines is a 2025 TOP100 Swiss Startups honoree. TOP100 Swiss Startups brings together the best "Made in Switzerland" start-ups and growing technology innovation enterprises, and is the benchmark ranking with the highest international influence in the field of Swiss science and technology innovation. Since 2011, this ranking has selected 100 of the most pioneering and market-promising Swiss innovative enterprises and 25 Swiss growing enterprises with the greatest unicorn potential across Switzerland every year, covering fields including life sciences, engineering machinery, robotics, information and communication, low-carbon technology, food technology, etc. The TOP100 Swiss Startups and its series of brand events are landmark activities in the Swiss innovation ecosystem, representing the highest peak of Swiss innovation and the forefront of international investment and financing.
The 2025 Chinese version of TOP100 Swiss Startups is published with honor by Insight Tech. Insight Tech is the authorized Chinese partner of TOP100 Swiss Startups, responsible for the operation and promotion of TOP100 Swiss Startups in China and assisting the ranking project in commercial cooperation with China. Insight Tech is a China-Europe (Switzerland) industrial innovation cooperation service provider, committed to promoting the localization of Swiss innovation in China and the internationalization of Chinese industries through ecological construction and cross-border empowerment.
To access the full list and industry-specific lists of TOP100 Swiss Startups, please visit the official WeChat account or official website of Insight Tech.